Close

China Jo-Jo Drugstores Announces the Fourth Quarter and Year End

Financial Results for Fiscal Year 2016 Q4 Gross Profit grew 29.0%, EPS increased to $0.05/share FY 2016 Revenue up 15.8%, Online Pharmacy Sales Increased 77.8%

June 28, 2016 9:00 AM EDT

HANGZHOU, China, June 28, 2016 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the "Company" or "China Jo-Jo"), a leading China-based pharmacy with retail, wholesale and online distribution of pharmaceutical and health care products through its own online and retail pharmacies, today announced financial results for the fourth quarter and fiscal year ended March 31, 2016.

FY 2016 Fourth Quarter Highlights:

  • Revenue was $20,468,616 for the fourth quarter ended March 31, 2016 as compared to $20,982,649 during the same period of last year
  • Gross profit increased to $4,311,559 from $3,341,109 in the same quarter of last year
  • Net income was $802,899 during the three months ended March 31, 2016, as compared to $519,423 in the fourth quarter of last year
  • Earnings per share (EPS) was $0.05/share, as compared to EPS of $0.03/share for the same quarter of last year

Fiscal Year 2016 Highlights:

  • Total revenue increased by $12,169,848 or 15.8% for the year ended March 31, 2016, as compared to the previous fiscal year
  • Retail drugstores sales increased by $2,405,908 or 4.9%, for the year ended March 31, 2016, as compared to the previous fiscal year
  • Online pharmacy sales increased 77.8% over FY 2015, to a record revenue of $26,449,981, which accounts for approximately 29.7% of the Company's overall sales
  • Gross profit increased by $5,073,557, or 40.8% year over year, while gross margin increased from 16.2% of FY 2015 to 19.7% of FY 2016
  • Net income was $447,156, and EPS was $0.03/share during FY 2016, as compared to net income of $855,628 and EPS of $0.06/share
  • The Company ended the year with cash and restricted cash balance of $20,419,863, $62.1 million in total assets, and $42.8 million in total liabilities

Reconciliation to non-GAAP Financial Measures

For The Years Ended

March 31

2016

2015

Net income

$447,156

$855,628

Share based compensation expense

1,022,790

1,020,306

Change in fair value of derivative liabilities

(612,198)

36,411

Adjusted net income

857,748

1,912,345

Adjusted net income per share - diluted

0.05

0.13

Revenue increase during FY 2016 was mainly due to the expansion of the Company's retail drugstores and online pharmacy business. Retail drugstores sales, which accounted for approximately 57.5% of total revenue, increased by approximately $2.4 million, of which a 3.5% increase in same-store sales contributed approximately $1.7 million while new stores sales contributed approximately $0.7 million. Excluding RMB depreciation effect, the same store sales increased by approximately 6.4% year over year. The same store sales are expected to continue to grow due to the increasing demand for healthcare products in China.

Online pharmacy sales reached $26,449,981, an increase of 77.8% over the previous year, thanks to the increased sales on e-commerce platform partners, such as Tmall, JD.com and yhd.com, as well as the enhanced amount of transactions on the Company's own online pharmacy website. To further expand the online presence of its pharmacy products, the Company launched its own branded stores on WeChat, China's leading mobile messaging app and social network with over 500 million active users. Meanwhile, sales on the Company's official online pharmacy website for the year ended March 31, 2016 increased by 233.2% from a year ago, primarily as a result of partnership with large insurance companies in China such as the People's Insurance Company (Group) of China Limited that refer their insurance customers to purchase qualified products through China Jo-Jo's website.

Chairman and CEO of China Jo-Jo, Mr. Liu Lei commented, "We achieved solid results in fiscal year 2016. We consolidated the operations of our retail drugstores and implemented key initiatives such as increasing product adaptability, providing access to mobile payments, and launching in-pharmacy virtual doctor clinics to drive sales and provide value-added services to our customers. We maintained profitability while migrating our product mix to higher margined pharmaceutical and health and wellness products. At the same time, our expansion in the fast-growing online pharmacy markets in China continues to outpace the industry. Our online pharmacy sales continued to grow rapidly through both third-party e-commerce platforms and our own online pharmacy website."

"Moving forward, our efforts will continue to focus on opening or acquiring more stores, creating deeper relationships with our customers, holding regional dominant market share in retail pharmacy, while taking a data-driven approach in identifying popular products and enhancing our abilities to promote online sales. We believe we have the right strategy for succeeding as a leading online and physical retail chain pharmacy stores in China."

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

March 31,

March 31,

2016

2015

ASSETS

CURRENT ASSETS

Cash

$

6,671,873

$

4,023,581

Restricted cash

13,747,990

8,992,101

Financial assets available for sale

465,165

1,307,200

Notes receivable

15,506

138,952

Trade accounts receivable, net of allowance for doubtful accounts of $2,099,244 and                         $2,870,818, as of March 31, 2016 and 2015, respectively

8,054,597

9,237,743

Inventories

10,802,691

10,538,591

Other receivables, net of allowance for doubtful accounts of $28,405 and $83,084, as of     March  31, 2016 and 2015, respectively

1,376,468

1,130,264

Advances to suppliers, net of allowance for doubtful accounts of $105,542 and $1,225,514, as    of March 31, 2016 and 2015, respectively

4,230,665

4,717,352

Other current assets

1,518,048

2,200,838

Total current assets

46,883,003

42,286,622

PROPERTY AND EQUIPMENT, net

5,543,076

7,056,781

OTHER ASSETS

Long-term investment

108,539

-

Farmland assets

1,562,205

1,704,359

Long term deposits

2,452,056

2,584,025

Other noncurrent assets

2,595,129

2,734,798

Intangible assets, net

2,928,779

3,142,003

Total other assets

9,646,708

10,165,185

Total assets

$

62,072,787

$

59,508,588

LIABILITIES AND STOCK HOLDERS' EQUITY

CURRENT LIABILITIES

Short-term loan payable

$

31,011

$

32,680

Accounts payable, trade

16,667,396

15,915,915

Notes payable

17,595,634

15,752,969

Other payables

1,917,821

2,931,869

Other payables - related parties

2,199,775

2,729,740

Loan from third parties

-

-

Customer deposits

2,610,151

3,759,050

Taxes payable

483,770

328,111

Accrued liabilities

615,056

509,537

Total current liabilities

42,120,614

41,959,871

Purchase option and warrants liability

636,301

315,327

Total liabilities

42,756,915

42,275,198

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY

Common stock; $0.001 par value; 250,000,000 shares authorized; 17,735,504 and 15,650,504    shares issued and outstanding as of March 31, 2016 and 2015

17,736

15,651

Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as    of March 31, 2016 and 2015

-

-

Additional paid-in capital

22,088,267

19,301,233

Statutory reserves

1,309,109

1,309,109

Accumulated deficit

(6,957,053)

(7,404,210)

Accumulated other comprehensive income

2,857,813

3,972,543

Total stockholders' equity

19,315,872

17,194,326

Non-controlling interests

-

39,064

Total equity

19,315,872

17,233,390

Total liabilities and stockholders' equity

$

62,072,787

$

59,508,588

 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

For the years endedMarch 31,

2016

2015

REVENUES, NET

$

89,065,580

$

76,895,732

COST OF GOODS SOLD

71,553,998

64,457,707

GROSS PROFIT

17,511,582

12,438,025

SELLING EXPENSES

12,360,872

10,416,451

GENERAL AND ADMINISTRATIVE EXPENSES

5,175,476

313,390

TOTAL OPERATING EXPENSES

17,536,348

10,729,841

INCOME FROM OPERATIONS

(24,766)

1,708,184

OTHER INCOME(EXPENSE), NET

(43,535)

295,018

IMPAIRMENT OF LONG-LIVED ASSETS

-

(1,053,765)

CHANGE IN FAIR VALUE OF PURCHASE OPTION AND WARRANTS LIABILITY

612,198

(36,411)

INCOME BEFORE INCOME TAXES

543,897

913,026

PROVISION FOR INCOME TAXES

96,741

57,398

NET INCOME

447,156

855,628

ADD: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST

-

(929)

NET INCOME ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.

$

447,156

$

856,557

NET INCOME

$

447,156

$

855,628

OTHER COMPREHENSIVE INCOME (LOSS)

Foreign currency translation adjustments

(1,114,730)

66,857

COMPREHENSIVE INCOME (LOSS)

(667,574)

922,485

Less: Comprehensive loss attributable to non-controlling interest

-

(1,479)

COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.

$

(667,574)

$

921,006

WEIGHTED AVERAGE NUMBER OF SHARES:

Basic

16,096,406

14,960,522

Diluted

16,147,505

15,156,423

EARNINGS (LOSS) PER SHARES:

Basic

$

0.03

$

0.06

Diluted

$

0.03

$

0.06

 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

Accumulated

Common Stock

Retained Earnings

other

Non-

Number of

Paid-in

Statutory

comprehensive

controlling

shares

Amount

capital

reserves

Unrestricted

income/(loss)

interest

Total

BALANCE, March 31, 2014                                              

14,416,022

14,416

17,355,555

1,309,109

(8,260,767)

3,905,136

(40,543)

$

14,363,992

Stock based compensation

615,000

615

1,003,872

1,004,487

Net income (loss)

856,557

(929)

855,628

Issuance of common stocks in exchange of debts

619,482

620

941,806

942,426

Foreign currency translation gain (loss)

67,407

(550)

66,857

BALANCE, March 31, 2015

15,650,504

$

15,651

19,301,233

1,309,109

(7,404,210)

3,972,543

39,064

$

17,233,390

Stock based compensation

885,000

885

1,021,906

1,022,791

Net income

447,157

447,157

 Registered direct offering financing

1,200,000

1,200

1,765,128

1,766,328

Foreign currency translation loss

(1,114,730)

(39,064)

(1,153,794)

BALANCE, March 31, 2016.

17,735,504

$

17,736

22,088,267

1,309,109

(6,957,053)

2,857,813

0

$

19,315,872

 

CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the year endedMarch 31,

2016

2015

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$

447,156

$

855,628

Adjustments to reconcile net income to net cash provided by operating activities:

Bad debt direct write-off and provision

(1,584,031)

(7,461,802)

Depreciation and amortization

1,456,029

2,820,489

Inventory reserve and write-off

-

(775,660)

Leasehold improvement and fixed assets impairment

-

1,053,765

Stock compensation

1,002,791

1,004,487

Change in fair value of purchase option derivative liability

(612,198)

36,411

Change in operating assets:

Accounts receivable, trade

432,677

(410,498)

Notes receivable

118,687

(138,187)

Inventories and biological assets

(762,212)

(2,970,350)

Other receivables

(67,778)

(920,961)

Advances to suppliers

1,329,323

5,266,390

Other current assets

581,847

(523,585)

Long term deposit

-

220,079

Other noncurrent assets

-

320,938

Change in operating liabilities:

Accounts payable, trade

1,595,739

1,255,589

Other payables and accrued liabilities

(598,213)

929,608

Customer deposits

(976,138)

548,534

Taxes payable

202,026

(47,657)

Net cash  provided by operating activities

2,585,705

1,063,218

CASH FLOWS FROM INVESTING ACTIVITIES:

Proceeds from sale of financial assets available for sale

790,845

-

Increase in financial assets available for sale

-

(1,307,200)

Acquisition of equipment

(192,937)

(1,283,997)

Increase in intangible assets-acquisition of Sanhao Pharmacy

-

(1,585,118)

Investment in a joint venture

(110,718)

-

Additions to leasehold improvements

(57,382)

(189,135)

Net cash provided by (used in) investing activities

429,808

(4,365,450)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from short-term bank loan

23,258

32,500

Repayment of short-term bank loan

(23,258)

(162,500)

Repayment of third parties loan

-

(294,405)

Change in restricted cash

(5,319,861)

(5,824,192)

Proceeds from notes payable

21,657,140

28,169,765

Repayment of notes payable

(18,956,792)

(20,333,918)

Changes in other payables-related parties

(481,879)

1,280,997

Proceeds from sale of stock and warrants

2,699,500

-

Net cash provided by (used in) financing activities

(401,892)

2,868,247

EFFECT OF EXCHANGE RATE ON CASH

34,671

12,290

INCREASE (DECREASE) IN CASH

2,648,292

(421,695)

CASH, beginning of year

4,023,581

4,445,276

CASH, end of year

$

6,671,873

$

4,023,581

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Cash paid for interest

$

155,578

$

56,366

Cash paid for income taxes

$

78,550

$

65,567

Issuance of common stocks in exchange of debts

$

-

$

941,613

Non-cash financing activities:

Issuance of stock purchase options to an investment bank

147,728

-

Use of non-GAAP financial measures

To supplement China Jo-Jo's consolidated financial results presented in accordance with GAAP, China Jo-Jo uses the following measures defined as non-GAAP financial measures by the SEC: net income (loss) excluding share-based compensation expenses and change in fair value of derivative liabilities, and diluted net income (loss) per share excluding share-based compensation expenses and change in the fair value of derivatives liabilities. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

China Jo-Jo believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding share-based compensation expenses and change in fair value of derivative liabilities that may not be indicative of its operating performance from a cash perspective. China Jo-Jo believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to China Jo-Jo's historical performance and liquidity. China Jo-Jo computes its non-GAAP financial measures using the same consistent method from quarter to quarter. China Jo-Jo believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using these non-GAAP measures is that they exclude share-based compensation and change in fair value of derivative liabilities charge that has been and will continue to be for the foreseeable future a significant recurring expense in our business. Management compensates for these limitations by providing specific information regarding the GAAP amounts excluded from each non-GAAP measure. The table under the heading Reconciliation to non-GAAP Financial Measures in the beginning of the release has more details on the reconciliations between GAAP financial measures that are most directly comparable to non-GAAP financial measures.

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of March 31, 2016, the Company had 58 retail pharmacies in Zhejiang Province, China. The Company's wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "estimate," "may," "will," "should," "project," "plan," "seek," "intend," "anticipate," the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company's internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations Contact:

Steve Liu [email protected]

Frank Zhao86-571-88077108 [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-jo-jo-drugstores-announces-the-fourth-quarter-and-year-end-300291226.html

SOURCE China Jo-Jo Drugstores, Inc.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases

Related Entities

Earnings, Definitive Agreement